M&A / Deals Eli Lilly maintains M&A streak with $202m Engage Bio buyout Pharmaceutical TechnologyEli Lilly's takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026. Read full story Post navigation Previous: FUJIFILM opens new iPSC facility in Madison, USNext: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
